← All First Tracks Biotherapeutics, INC filings

First Tracks Biotherapeutics, INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

NASDAQ

15 Oct 2026

TRAX

First Tracks Biotherapeutics, INC

8-K: First Tracks Biotherapeutics Secures $200M Private Placement

First Tracks Biotherapeutics announced a $200 million private placement of common stock to fund general corporate purposes and clinical development.

NASDAQ

13 Oct 2026

TRAX

First Tracks Biotherapeutics, INC

8-K: First Tracks Biotherapeutics Reports Positive Celiac Disease Trial Data

First Tracks Biotherapeutics announced positive top-line results from its Phase 1b trial of ANB033 in celiac disease, showing significant protection against intestinal damage and symptoms.

NASDAQ

12 Aug 2026

TRAX

First Tracks Biotherapeutics, INC

8-K: First Tracks Biotherapeutics Q2 2026 Update: ANB033 Progress

First Tracks Biotherapeutics reported Q2 2026 financial results, highlighting progress in its ANB033 clinical trials for celiac disease and eosinophilic esophagitis, alongside a positive FDA Fast Track designation.